| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10964827 | Vaccine | 2015 | 7 Pages |
Abstract
In this randomized, controlled trial among 300 children aged 24 through 59 months in urban Bangladesh, Russian-backbone LAIV was safe and well tolerated. Further evaluation of LAIV safety and efficacy in a larger cohort is warranted.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Justin R. Ortiz, Doli Goswami, Kristen D.C. Lewis, Amina Tahia Sharmeen, Moshtaq Ahmed, Mustafizur Rahman, Mohammed Z. Rahman, Jodi Feser, Kathleen M. Neuzil, W. Abdullah Brooks,